

Buy-back of ordinary shares in BONESUPPORT HOLDING AB September 1-4, 2026 (week 36)

BONESUPPORT HOLDING AB (LEI CODE: 549300COLY053IGTLD63) ("BONESUPPORT") has during September 1, 2026 up to and including September 4, 2026 repurchased a total of 44,000 own ordinary shares (ISIN: SE0009858152) as part of the buy-back program initiated by BONESUPPORT on September 1, 2026

The repurchases are part of the buy-back program of maximum SEK 100 million announced by BONESUPPORT on September 1, 2026 and which started on September 1, 2026 and will end no later than October 30, 2026. The buy-back program is carried out for the purpose of adapting BONESUPPORT's capital structure to the company's capital needs and thereby contribute to increased shareholder value. The repurchases are carried out in accordance with the Market Abuse Regulation (EU) 596/2014 ("MAR") and the European Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation").

Ordinary shares in BONESUPPORT have been repurchased as follows:

Date	Aggregate daily volume (number of shares)	Weighted average price per day (SEK)	Total Daily Transaction Value (SEK)
September 1, 2026	8,000	227.2449	1,817,959
September 2, 2026	12,000	227.9246	2,735,095
September 3, 2026	12,000	232.8597	2,794,317
September 4, 2026	12,000	230.5851	2,767,021
Total during week 36	44,000	229.8725	10,114,931
Total accumulated during buy-back program	44,000	229.8725	10,114,931

All repurchases have been carried out on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) on behalf of BONESUPPORT. Following the above repurchases, BONESUPPORT's holding of treasury shares up to and including September 4, 2026 amounts to 417,320 ordinary shares and 905,155 Series C shares.

As of September 4, 2026, the total number of shares in BONESUPPORT, including treasury shares, is 66,764,350, of which 65,859,195 are ordinary shares and 905,155 are Series C shares. The total number of outstanding shares in BONESUPPORT, excluding treasury shares, is 65,441,875, all of which are ordinary shares.

Complete information about the transactions carried out in accordance with Article 5.3 of MAR and Article 2.3 of the Safe Harbour Regulation is attached to this press release.

For more information contact:

BONESUPPORT Holding AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

Buy-back of ordinary shares in BONESUPPORT HOLDING AB September 1-4, 2026 (week 36)
Appendix Repurchase Of Shares W 36